Newsfeeds Archive - Spark Newswire

1 minute read

Aptose Announces $4.43M Registered Direct Offering Of 3.855M Shares Of Common Stock At A Price Of $1.15/Share, Priced At-the-Market Under Nasdaq Rules

May 31, 8:09 AM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today

APTO

1 minute read

Aptose Announces Pricing Of Underwritten Offering Of 4,912,280 Shares At $1.71 Per Share And Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

By Benzinga Newsdesk

January 26, 9:04 AM

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated

APTO

2 minute read

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

January 26, 8:58 AM

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

APTO

1 minute read

Events
News

Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML

By Charles Gross

December 10, 9:14 AM

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic

APTO

22 minute read

Earnings

Earnings Scheduled For November 9, 2023

By Benzinga Insights

November 9, 7:52 AM

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

AAOI

1 minute read

Aptose Tuspetinib Clinical Data Selected For Oral Presentation At The 2023 ASH Annual Meeting

By Benzinga Newsdesk

November 2, 9:10 AM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today

APTO

3 minute read

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

October 30, 1:55 PM

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

ACLS